Logo image of 88Q.DE

4BASEBIO PLC (88Q.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:88Q - GB00BMCLYF79 - Common Stock

8.05 EUR
-0.15 (-1.83%)
Last: 11/13/2025, 7:00:00 PM
Fundamental Rating

3

Overall 88Q gets a fundamental rating of 3 out of 10. We evaluated 88Q against 77 industry peers in the Biotechnology industry. While 88Q seems to be doing ok healthwise, there are quite some concerns on its profitability. 88Q is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year 88Q has reported negative net income.
In the past year 88Q has reported a negative cash flow from operations.
In the past 5 years 88Q always reported negative net income.
In the past 5 years 88Q always reported negative operating cash flow.
88Q.DE Yearly Net Income VS EBIT VS OCF VS FCF88Q.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of 88Q (-39.08%) is comparable to the rest of the industry.
88Q has a Return On Equity (-75.90%) which is in line with its industry peers.
Industry RankSector Rank
ROA -39.08%
ROE -75.9%
ROIC N/A
ROA(3y)-45.31%
ROA(5y)-32.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
88Q.DE Yearly ROA, ROE, ROIC88Q.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

88Q has a Gross Margin (61.55%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of 88Q has declined.
The Profit Margin and Operating Margin are not available for 88Q so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.33%
GM growth 5YN/A
88Q.DE Yearly Profit, Operating, Gross Margins88Q.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

88Q does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 88Q has been increased compared to 1 year ago.
The number of shares outstanding for 88Q has been increased compared to 5 years ago.
88Q has a better debt/assets ratio than last year.
88Q.DE Yearly Shares Outstanding88Q.DE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M
88Q.DE Yearly Total Debt VS Total Assets88Q.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

88Q has an Altman-Z score of 2.08. This is not the best score and indicates that 88Q is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.08, 88Q is in the better half of the industry, outperforming 69.23% of the companies in the same industry.
88Q has a Debt/Equity ratio of 0.81. This is a neutral value indicating 88Q is somewhat dependend on debt financing.
88Q has a worse Debt to Equity ratio (0.81) than 60.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF N/A
Altman-Z 2.08
ROIC/WACCN/A
WACC8.5%
88Q.DE Yearly LT Debt VS Equity VS FCF88Q.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

88Q has a Current Ratio of 11.36. This indicates that 88Q is financially healthy and has no problem in meeting its short term obligations.
88Q has a better Current ratio (11.36) than 93.59% of its industry peers.
88Q has a Quick Ratio of 11.15. This indicates that 88Q is financially healthy and has no problem in meeting its short term obligations.
88Q has a Quick ratio of 11.15. This is amongst the best in the industry. 88Q outperforms 93.59% of its industry peers.
Industry RankSector Rank
Current Ratio 11.36
Quick Ratio 11.15
88Q.DE Yearly Current Assets VS Current Liabilites88Q.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

7

3. Growth

3.1 Past

88Q shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -26.52%.
The Revenue has grown by 198.49% in the past year. This is a very strong growth!
88Q shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.80% yearly.
EPS 1Y (TTM)-26.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.8%
Revenue 1Y (TTM)198.49%
Revenue growth 3Y40.28%
Revenue growth 5Y35.8%
Sales Q2Q%257.93%

3.2 Future

Based on estimates for the next years, 88Q will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.34% on average per year.
88Q is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 97.36% yearly.
EPS Next Y-34.32%
EPS Next 2Y-7.14%
EPS Next 3Y2.5%
EPS Next 5Y10.34%
Revenue Next Year50%
Revenue Next 2Y141.52%
Revenue Next 3Y132.08%
Revenue Next 5Y97.36%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
88Q.DE Yearly Revenue VS Estimates88Q.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
88Q.DE Yearly EPS VS Estimates88Q.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 88Q. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 88Q. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
88Q.DE Price Earnings VS Forward Price Earnings88Q.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
88Q.DE Per share data88Q.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.14%
EPS Next 3Y2.5%

More info and screens

0

5. Dividend

5.1 Amount

88Q does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

4BASEBIO PLC

FRA:88Q (11/13/2025, 7:00:00 PM)

8.05

-0.15 (-1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-23 2024-09-23
Earnings (Next)N/A N/A
Inst Owners13.48%
Inst Owner ChangeN/A
Ins Owners10.92%
Ins Owner ChangeN/A
Market Cap125.10M
Revenue(TTM)1.78M
Net Income(TTM)-14.41M
Analysts84.44
Price Target20.21 (151.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.63%
PT rev (3m)0.15%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-122.11%
EPS NY rev (3m)-122.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-34.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 61.9
P/FCF N/A
P/OCF N/A
P/B 5.8
P/tB 7.24
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.01
OCFYN/A
SpS0.13
BVpS1.39
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -39.08%
ROE -75.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.55%
FCFM N/A
ROA(3y)-45.31%
ROA(5y)-32.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.33%
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 152.56%
Cap/Sales 85.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.36
Quick Ratio 11.15
Altman-Z 2.08
F-Score4
WACC8.5%
ROIC/WACCN/A
Cap/Depr(3y)276.3%
Cap/Depr(5y)321.58%
Cap/Sales(3y)395.7%
Cap/Sales(5y)363.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.8%
EPS Next Y-34.32%
EPS Next 2Y-7.14%
EPS Next 3Y2.5%
EPS Next 5Y10.34%
Revenue 1Y (TTM)198.49%
Revenue growth 3Y40.28%
Revenue growth 5Y35.8%
Sales Q2Q%257.93%
Revenue Next Year50%
Revenue Next 2Y141.52%
Revenue Next 3Y132.08%
Revenue Next 5Y97.36%
EBIT growth 1Y-44.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.55%
EBIT Next 3Y6.42%
EBIT Next 5Y15.28%
FCF growth 1Y-134.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-163.49%
OCF growth 3YN/A
OCF growth 5YN/A

4BASEBIO PLC / 88Q.DE FAQ

Can you provide the ChartMill fundamental rating for 4BASEBIO PLC?

ChartMill assigns a fundamental rating of 3 / 10 to 88Q.DE.


What is the valuation status for 88Q stock?

ChartMill assigns a valuation rating of 0 / 10 to 4BASEBIO PLC (88Q.DE). This can be considered as Overvalued.


How profitable is 4BASEBIO PLC (88Q.DE) stock?

4BASEBIO PLC (88Q.DE) has a profitability rating of 1 / 10.


How financially healthy is 4BASEBIO PLC?

The financial health rating of 4BASEBIO PLC (88Q.DE) is 5 / 10.